BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daxor Corporation (DXR) Announces Filing of Form N-CSR for December 31, 2012 and Volumex Kit Sales for 2012


3/1/2013 9:42:55 AM

NEW YORK, NY--(Marketwire - March 01, 2013) -

Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of December 31, 2012. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-12312012.pdf.

At December 31, 2012, the Company had net assets of $35,113,819 or $8.50 per share versus net assets of $35,327,185 or $8.41 per share at December 31, 2011. The Company's Return on Average Net Assets for the year was 1.05%.

Net assets resulting from investments increased by $1,186,968 during the year ended December 31, 2012. However, in total, net assets decreased during the year by $213,366. This was partially due to the purchase of 69,003 shares of treasury stock for $572,786 and total dividends paid of $833,386.

The Company paid a total dividend of $0.20 per share in 2012. The dividend was paid as follows: $0.10 per share on August 24th and December 27th.

The Company's investment policy is to maintain a minimum of 80% of its portfolio in electric utilities. At December 31, 2012, investments in electric utilities made up 83.9% of the value of the Company's portfolio. Dividends from the Company's investments in electric utilities made up 83.4% of the Company's total dividend income for the year ended December 31, 2012. The Company is receiving dividend income on 67 of the 80 common and preferred stocks in its investment portfolio at December 31, 2012.

The portfolio turnover rate for the year ended December 31, 2012 was 18.92% which indicates an average holding period in excess of five years for our investment portfolio. The investment approach of management is to buy stocks which it is prepared to hold for the long term. There are stocks in our portfolio which we have held in excess of 20 years.

At December 31, 2012, net fair value over cost of the Company's securities portfolio totaled $24,293,834. This was comprised of net fair value over cost of $26,003,472 and net cost over fair value of $(1,709,638).

The Company's results from investments for the year ended December 31, 2012 are disclosed in greater detail in the Form N-CSR which will be filed today.

For the year ended December 31, 2012, the Company's revenue from the sale of Volumex Kits decreased by 2% from the same period in 2011. There were 70 Blood Volume Analyzers in service at December 31, 2012 versus 58 instruments at December 31, 2011. There is additional disclosure regarding the Company's medical instrumentation and biotechnology operations in the Form N-CSR for December 31, 2012.

The Company sent sales representatives to promote the BVA-100 Blood Volume Analyzer to 20 medical trade shows and conventions during 2012. Trade shows and conventions are an important way for Daxor to publicize the benefits of the BVA-100.

Dr. Joseph Feldschuh, the President of Daxor, said: "We are somewhat disappointed that our Volumex kit sales did not increase in 2012. However, we are guardedly optimistic about sales for 2013 because of the increase in Blood Volume Analyzers in service and the additional salespeople that we have hired. We realize there are no guarantees but remain hopeful that members of the medical community will understand the need for measuring patients' blood volume precisely rather than using surrogate tests and clinical guesstimates which can be grossly inaccurate. The precise knowledge of a patient's blood volume is essential for optimally treating critically ill medical and surgical patients. Our goal is to make blood volume measurement a standard of care for any patient experiencing a blood volume derangement."


Contact Information:
Daxor Corporation
David Frankel
212-330-8504
Chief Financial Officer
Email Contact

Diane Meegan
212-330-8512
Investor Relations
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES